Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group study

Lawrence H. Einhorn, Kenneth Pennington, John McClean

Research output: Contribution to journalArticle

75 Scopus citations

Abstract

Twenty-six previously treated patients with refractory small cell lung cancer (SCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. Twenty-five patients had prior exposure to cisplatin plus etoposide, and 14 of the 26 patients (54%) had prior therapy with CAV (cyclophosphamide, doxorubicin, and vincristine). Nonhematologic toxicity was mild; the dose-limiting toxicity was granulocytopenia. One complete response and five partial responses were seen (duration, 6 to 20 weeks), for an overall response rate of 23%. We conclude that daily oral etoposide is a well-tolerated and easily administered drug in refractory SCLC and has definite therapeutic activity.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalSeminars in oncology
Volume17
Issue number1 SUPPL. 2
StatePublished - Feb 1990

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group study'. Together they form a unique fingerprint.

  • Cite this